中华老年医学杂志
中華老年醫學雜誌
중화노년의학잡지
Chinese Journal of Geriatrics
2012年
12期
1044-1047
,共4页
李作成%马洪俊%王一然%李曦铭%胡越成%赵茹%肖建勇%付乃宽%丛洪良
李作成%馬洪俊%王一然%李晞銘%鬍越成%趙茹%肖建勇%付迺寬%叢洪良
리작성%마홍준%왕일연%리희명%호월성%조여%초건용%부내관%총홍량
激肽原类%急性肾功能不全%尿酸
激肽原類%急性腎功能不全%尿痠
격태원류%급성신공능불전%뇨산
Kininogens%Acute kidney injury%Uric acid
目的 观察术前联用不同剂量阿托伐他汀与普罗布考对老年冠心病患者对比剂急性肾损伤(CIAKI)和血尿酸的影响.方法 接受择期冠状动脉造影(CAG)或经皮冠状动脉支架植入术(PCI)的老年冠心病患者121例,随机分为标准联合剂量治疗(标准联合)组35例:阿托伐他汀每晚顿服20 mg及普罗布考250 mg,3次/d,术前无强化;强化联合剂量治疗(强化联合)组41例:阿托伐他汀每晚顿服40 mg及普罗布考250 mg,3次/d,术前2h顿服阿托伐他汀40 mg普罗布考500 mg;强化剂量治疗(强化)组45例:阿托伐他汀每晚顿服40 mg,术前2h顿服阿托伐他汀40 mg.所有患者术前、术后24 h抽取静脉血检测血尿素、肌酐、尿酸,肾脏病膳食改良试验(MDRD)方法估算肾小球滤过率.留取静脉血和术前清晨第一次中段尿液及术后24 h尿液测定中性粒细胞明胶酶相关脂质运载蛋白(NGAL)浓度.结果 (1)与术前比较,强化联合和强化组术后血尿素均下降,(5.6±1.4)mmol/L与(4.7±0.9) mmol/L、(5.3±1.2) mmol/L与(4.8±1.2)mmol/L(P<0.01,P<0.05),血肌酐和肾小球滤过率变化差异无统计学意义;标准联合组术后肾小球滤过率下降,(76.2±14.3)ml· min-1·1.73 m-2与(71.9±17.9) ml·min-1· 1.73 m-2(P<0.05);术后只有强化联合组血尿酸下降(P<0.01).(2)标准联合组术后尿NGAL升高,其尿NGAL变化值较其他两组高(均P<0.01).结论 术前联用阿托伐他汀40 mg和普罗布考250 mg,3次/d,或单用阿托伐他汀40 mg,均可改善CIAKI,只有强化联合方式在短期内可降低血尿酸.
目的 觀察術前聯用不同劑量阿託伐他汀與普囉佈攷對老年冠心病患者對比劑急性腎損傷(CIAKI)和血尿痠的影響.方法 接受擇期冠狀動脈造影(CAG)或經皮冠狀動脈支架植入術(PCI)的老年冠心病患者121例,隨機分為標準聯閤劑量治療(標準聯閤)組35例:阿託伐他汀每晚頓服20 mg及普囉佈攷250 mg,3次/d,術前無彊化;彊化聯閤劑量治療(彊化聯閤)組41例:阿託伐他汀每晚頓服40 mg及普囉佈攷250 mg,3次/d,術前2h頓服阿託伐他汀40 mg普囉佈攷500 mg;彊化劑量治療(彊化)組45例:阿託伐他汀每晚頓服40 mg,術前2h頓服阿託伐他汀40 mg.所有患者術前、術後24 h抽取靜脈血檢測血尿素、肌酐、尿痠,腎髒病膳食改良試驗(MDRD)方法估算腎小毬濾過率.留取靜脈血和術前清晨第一次中段尿液及術後24 h尿液測定中性粒細胞明膠酶相關脂質運載蛋白(NGAL)濃度.結果 (1)與術前比較,彊化聯閤和彊化組術後血尿素均下降,(5.6±1.4)mmol/L與(4.7±0.9) mmol/L、(5.3±1.2) mmol/L與(4.8±1.2)mmol/L(P<0.01,P<0.05),血肌酐和腎小毬濾過率變化差異無統計學意義;標準聯閤組術後腎小毬濾過率下降,(76.2±14.3)ml· min-1·1.73 m-2與(71.9±17.9) ml·min-1· 1.73 m-2(P<0.05);術後隻有彊化聯閤組血尿痠下降(P<0.01).(2)標準聯閤組術後尿NGAL升高,其尿NGAL變化值較其他兩組高(均P<0.01).結論 術前聯用阿託伐他汀40 mg和普囉佈攷250 mg,3次/d,或單用阿託伐他汀40 mg,均可改善CIAKI,隻有彊化聯閤方式在短期內可降低血尿痠.
목적 관찰술전련용불동제량아탁벌타정여보라포고대노년관심병환자대비제급성신손상(CIAKI)화혈뇨산적영향.방법 접수택기관상동맥조영(CAG)혹경피관상동맥지가식입술(PCI)적노년관심병환자121례,수궤분위표준연합제량치료(표준연합)조35례:아탁벌타정매만돈복20 mg급보라포고250 mg,3차/d,술전무강화;강화연합제량치료(강화연합)조41례:아탁벌타정매만돈복40 mg급보라포고250 mg,3차/d,술전2h돈복아탁벌타정40 mg보라포고500 mg;강화제량치료(강화)조45례:아탁벌타정매만돈복40 mg,술전2h돈복아탁벌타정40 mg.소유환자술전、술후24 h추취정맥혈검측혈뇨소、기항、뇨산,신장병선식개량시험(MDRD)방법고산신소구려과솔.류취정맥혈화술전청신제일차중단뇨액급술후24 h뇨액측정중성립세포명효매상관지질운재단백(NGAL)농도.결과 (1)여술전비교,강화연합화강화조술후혈뇨소균하강,(5.6±1.4)mmol/L여(4.7±0.9) mmol/L、(5.3±1.2) mmol/L여(4.8±1.2)mmol/L(P<0.01,P<0.05),혈기항화신소구려과솔변화차이무통계학의의;표준연합조술후신소구려과솔하강,(76.2±14.3)ml· min-1·1.73 m-2여(71.9±17.9) ml·min-1· 1.73 m-2(P<0.05);술후지유강화연합조혈뇨산하강(P<0.01).(2)표준연합조술후뇨NGAL승고,기뇨NGAL변화치교기타량조고(균P<0.01).결론 술전련용아탁벌타정40 mg화보라포고250 mg,3차/d,혹단용아탁벌타정40 mg,균가개선CIAKI,지유강화연합방식재단기내가강저혈뇨산.
Objective To observe the effect of different doses of atorvastatin combined with probucol on contrast induced acute kidney injury (CIAKI) and serum uric acid in elderly patients.Methods Totally 121 cases admitted for coronary angioplasty were randomly divided into three groups.In standard combining treatment group (n=35),atorvastatin 20 mg qn and probucol 0.25 g,tid were given with no loading dose intake before angioplasty.In intensively combined treatment group (n=41),atorvastatin 40mg qn and probucol 0.25 g,tid were given with a loading dose of atorvastatin 40 mg and probucol 0.5 g at 2 hours before angioplasty.In intensive atorvastatin therapy group(n=45),atorvastatin 40 mg qn were given,with a loading dose of atorvastatin 40 mg 2 hours before angioplasty.All patients were then evaluated 24 hours before and after angioplasty procedure,and their blood urea nitrogen (BUN),serum creatinine (Scr),serum uric acid (SUA),estimated glomerular filtration rate (eGFR) by modified diet in renal disease study (MDRD) method were tested.The serum and urine at 24 hours before and after operation were collected.Neutrophil gelatinase associated lipocalin (NGAL) were determinated by enzyme linked immunosorbnent assay (ELISA) method.Results After operation,eGFR was decreased in standard combining treatment group [(76.2±14.3) ml· min-1 · 1.73 m-2 vs.(71.9±17.9) ml· min-1 · 1.73 m-2,P<0.05],while Scr,eGFR and uNGAL showed no changes in intensively combining treatment group and intensive atorvastatin therapy group (P>0.05) ; BUN in the two groups was decreased [(5.6± 1.4)mmol/L vs.(4.7±0.9) mmol/L,(5.3±1.2) mmol/L vs.(4.8±1.2) mmol/L,P<0.01,P<0.05].SUA was reduced in intensively combining treatment group (P < 0.05).uNGAL was increased in standard combining treatment group (P < 0.05).Conclusions For elderly patients,intensive atorvastatin therapy and combining intensive treatment can both improve CIAKI.Only combination and intensive treatment benefit for decrease of uric acid.